ClinicalTrials.gg

Fatigue clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,232 studies for Fatigue across more than 10 countries. 427 are recruiting or about to start. 783 of them are mainly about Fatigue (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 2 narrower conditions too, such as Mental Fatigue: 2,427 studies, 486 open.

ClinicalTrials.gov finds 3,630 studies for Fatigue. How that becomes 2,232 here

This page counts the studies the registry files under Fatigue, and those it files under no condition that list Fatiguethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 3,630Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −194Filed under a narrower condition, counted on its own pageMental Fatigue 136 · Compassion Fatigue 58
  3. −328List Fatigue as a condition, but the registry did not file them under itMost often written as “Chronic Fatigue Syndrome” (108), “Fatigue Syndrome, Chronic” (34), and “Cancer-Related Fatigue” (27). The registry filed 1 of them under no condition at all, and the others under other conditions only, most often Fatigue Syndrome, Chronic (174) and Fibromyalgia (32).
  4. −876Match it another way711 name it in the title, 125 in a keyword, and 40 by a synonym or other text the search reads.
  5. 2,232The count on this page141 of them list Fatigue in their own words; the registry filed them under no condition.

Status

Completed
1,362
Recruiting
239
Status unknown
191
Not yet recruiting
150
Terminated
104
Active, not recruiting
82

Phase

Phase 2
191
Phase 3
115
Phase 4
65
Phase 1
54
Early Phase 1
13

Where

United States
704
Turkey
332
France
105
Canada
88
Taiwan
86
Spain
79

Who develops what

Add Fatigue to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 11 companies, 4 with this as their studies’ main aim; 5 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Alkermes, Changchun GeneScience Pharmaceutical and Harmony Biosciences here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CannabidiolRecent, limited
Evidence
  • NCT05942911 · Incannex Healthcare Ltd · Phase 2 · comparator · “Cannabidiol” · registered May 2023
Jazz Pharmaceuticals46% of its industry studiesUS: JAZZ PHARMS RES (FDA 2018)EU: Jazz Pharmaceuticals (EMA 2019)11 study
HydroxychloroquineRecent, limited
Evidence
  • NCT05942911 · Incannex Healthcare Ltd · Phase 2 · comparator · “Hydroxychloroquine” · registered May 2023
Sanofi13% of its industry studiesUS: off-patent, 11 generics marketed11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Nuvastatic☆ Track1 live phase-3 study: NCT07669519Natureceuticals Sdn Bhd
ianalumab☆ Track1 live phase-3 study: NCT07621809Novartis

The 2 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Mar 2027 est.Nuvastatic · Natureceuticals Sdn Bhd · Phase 3 main aimNCT07669519 Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy — primary endpoint: Changes in cancer-related fatigue in colon cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo. · 180 enrolled
  • May 2027 est.alixorexton · Alkermes, Inc. · Phase 3 registry mapping onlyNCT07455383 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 — primary endpoint: Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level · 150 enrolled
  • Aug 2027 est.Rimonabant · Sinfatin S.L · Phase 2 main aimNCT07843108 Effect of Rimonabant on Hand Function in Patients With Spinal Cord Injury — primary endpoint: Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP). · 8 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Fatigue studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Stimulants 7 open · PDE5 inhibitors 1 open · Corticosteroids 11 · SNRIs 9 · Potassium channel blockers 7

Coming up

144studies finish main data collection within a year8 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 239 Fatigue studies recruiting now, 111 (46%) set no upper age limit and 98 (41%) stop at 75 or younger. 23 (10%) take children under 18. 23 (10%) are for women only and 9 (4%) for men only; 73 (31%) take healthy volunteers.

Recruiting studies that take each age, of 239
AgeWomenMen
1014 (6%)16 (7%)
18187 (78%)186 (78%)
30203 (85%)190 (79%)
40204 (85%)187 (78%)
50200 (84%)183 (77%)
65185 (77%)173 (72%)
75150 (63%)140 (59%)
85125 (52%)117 (49%)

Across all 2,232 studies, recruiting or not: 45% stop at 75 or younger and 36% at 65; 9% take children; 14% are for women only and 6% for men only; 32% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Fatigue studies take

Of 43 phase 2 interventional studies under Fatigue, half reached primary completion within 38 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 123 mo9–40 · 17 studies——
Phase 238 mo20–48 · 43 studies—44 mo26–90 · 35 studies
Phase 331 mo24–61 · 27 studies——
Phase 433 mo21–55 · 15 studies——
Interventional, no phase12 mo5–27 · 989 studies3 mo2–10 · 53 studies12 mo5–27 · 936 studies
Observational24 mo7–39 · 166 studies—22 mo7–45 · 156 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered18

Show 13 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,232. Browse all 2,232 → or search them.